Business Wire

Merz Venture Initiative Increases Investment in Cytrellis

Share

Merz, a global leader in medical aesthetics and neurotoxins, announced today that it has increased its investment in US-based medical technology company Cytrellis Biosystems, Inc. via its corporate venture initiative. An investor since April 2016, Merz most recently participated in Cytrellis’ $28.5 million Series B financing. Additionally, Michael Peterson, CTO – Merz Device Innovation Center and representative of the Merz venture initiative, will join the Board of Directors at Cytrellis.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180605006027/en/

“This new round of investment reflects Merz’s confidence in both the technology and the leadership at Cytrellis,” said Jörg Bergler, Head of Global Corporate Development at Merz. “We have seen excellent progress since our initial investment and are pleased to further support the company’s ongoing clinical, product development and regulatory activities.”

Cytrellis is a Boston-based clinical stage company that has been developing an entirely new category of medical devices for the aesthetics market. Cytrellis’ key proprietary technology removes excess skin without invasive surgery or scarring. This technology will enable physicians to improve sagging skin associated with aging on the face and other areas of the body and thereby address one of the aesthetic industry’s largest unmet needs.

“We are pleased Merz’ venture initiative has continued to invest as part of our Series B round, which will allow Cytrellis to conclude clinical studies and fund our efforts to obtain regulatory clearances,” said Karen Cronholm, President and CEO of Cytrellis. “Additionally, we welcome the expertise of Mr. Peterson from Merz to our board of directors. Mr. Peterson has been involved in leading the development of multiple dermatologic devices, including Ultherapy® and Cellfina®.”

Through its corporate venture initiative, Merz continues to invest in promising early-stage aesthetic companies. In particular, Merz seeks proactive and long-term engagement with selected partners, with the goal of providing value beyond funding, including access to relevant experts and valuable commercial insight.

For more information about Merz’s corporate venture initiative, please visit https://www.merz.com/innovation/venture-initiative/.

About Merz

With approximately 3,000 employees and a direct presence in 28 countries, Merz is a global, family-owned medical aesthetics and neurotoxin company based in Frankfurt, Germany. Privately held for 110 years, the company is distinguished by its commitment to innovation, solid financial strength and continuous growth. In addition to its comprehensive portfolio of medical aesthetic products in the device, injectable and skincare categories, Merz also develops neurotoxin therapy to treat neurologically-induced movement disorders. In fiscal year 2016/17, Merz generated revenue of EUR 1,092.9 million. More information is available at www.merz.com.

About Cytrellis Biosystems

Cytrellis Biosystems, Inc. is a clinical stage medical technology company developing a new, proprietary class of aesthetic devices. Our devices are designed to remove sagging skin associated with aging without surgery or scarring, enabling aesthetic practitioners an unprecedented ability to improve age related changes in skin and restore youthful beauty. Cytrellis is dedicated to working with leading physicians and partners to develop unique product solutions, which emphasize safety, clinical results and improved quality of life. For more information about Cytrellis Biosystems, please visit www.cytrellis.com

Contact information

Merz Contact:
Merz Pharma GmbH & Co. KGaA
Global Corporate Communications
Mariana Smith Bourland
Phone: +49 151 4249 1466
Email: mariana.smith@merz.com
or
Cytrellis Contact:
Info@cytrellis.com
+1 857.254.1720

About Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Velodyne Lidar Acquires Mapper.ai for ADAS Launch23.7.2019 15:00:00 CESTPress release

Velodyne Lidar, Inc. today announced it has acquired mapping and localization software as well as intellectual property assets from Mapper.ai. Mapper technology will enable Velodyne to accelerate development of Vella™, breakthrough software that establishes its directional view Velarray™ lidar sensor. The Velarray is the first solid-state Velodyne lidar sensor that is embeddable and fits behind a windshield, as an integral component for superior, more effective advanced driver assistance systems (ADAS). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190723005257/en/ In addition to ADAS, Velodyne will incorporate Mapper technology into lidar-centric solutions for other emerging applications, including autonomous vehicles, last-mile delivery services, security, smart cities, smart agriculture, robotics, and unmanned aerial vehicles. (Photo: Business Wire) Mapper’s entire leadership and engineering teams will join Velodyne, bol

Gilead Presents New Findings on Profile of Descovy® for Potential Use as HIV Pre-exposure Prophylaxis Compared With Truvada®23.7.2019 15:00:00 CESTPress release

Gilead Sciences, Inc. (NASDAQ: GILD) today presented additional results from the DISCOVER trial evaluating an investigational use of Descovy (emtricitabine 200 mg and tenofovir alafenamide 25 mg tablets; F/TAF) for HIV pre-exposure prophylaxis (PrEP). In a sub-analysis of the DISCOVER trial, Descovy reached intracellular drug concentration levels above the estimated protective threshold significantly more quickly than Truvada (emtricitabine 200 mg and tenofovir disoproxil fumarate 300 mg tablets; F/TDF), and additional pharmacokinetic data confirm that these drug concentration levels persist longer than Truvada. The results were presented at the 10th International AIDS Society Conference on HIV Science (IAS 2019) being held in Mexico City. “Gilead is committed to driving advances in HIV prevention and supporting broader public health initiatives that are designed to reduce HIV infections,” said Diana Brainard, MD, Senior Vice President, HIV and Emerging Viruses, Gilead Sciences. “These

Wealthy Americans are increasingly willing to invest, new UBS survey finds23.7.2019 14:12:00 CESTPress release

US high net worth individuals and business owners are expressing growing intentions to invest as US markets continue to hit record highs in 2019, according to UBS Global Wealth Management's new quarterly Investor Sentiment survey. The survey, which polled more than 3,800 wealthy investors and entrepreneurs in 17 countries, also shows US investors remain positive on the U.S. stock market but continue to rank politics and the national debt as top concerns. Fifty percent of US investors see a diversified portfolio as a hedge against US-China trade tensions specifically, in line with UBS GWM's own views, compared with 41% who favor cash. Filippo Ilardi, US Client Strategy Officer at UBS Global Wealth Management, says: "We are pleased to see a substantial increase in investors willing to put more money in the market. Wealthy Americans are concerned about the political environment and US-China trade tensions but we are encouraged that they see diversification as an important way of managing

Andersen Global Expands into Ghana23.7.2019 13:30:00 CESTPress release

Ghana law firm, Sam Okudzeto & Associates, signed a collaboration agreement with Andersen Global, marking Andersen Global’s presence in 13 African countries and over 51 countries worldwide. Located in the capital of Accra, Sam Okudzeto & Associates is one of the largest law firms in Ghana. For the past 48 years, the firm has provided legal advice and guidance in the corporate and commercial areas, including patents and trademarks, mergers and acquisition, tax advisory, corporate banking, international trade and investment, debt recovery, mining and mineral law, industrial and labor, aviation, maritime law, petroleum oil and gas, and intellectual property. Sam Okudzeto & Associates founder and Managing Partner, Sam Okudzeto and Nene Amegatcher, have led the team since the establishment of the firm until Nene Amegatcher was elevated to the Supreme Court. The firm now has four partners and 18 lawyers who have gained international reputation for their keen knowledge and experience with Alt

Seoul Semiconductor Switches to Rimini Street for SAP Support23.7.2019 13:00:00 CESTPress release

Rimini Street, Inc. (Nasdaq: RMNI), a global provider of enterprise software products and services, the leading third-party support provider for Oracle and SAP software products and a Salesforce partner, today announced that Seoul Semiconductor, a global LED development and manufacturing company headquartered in South Korea, has switched from SAP to Rimini Street for support of its SAP ECC 6.0 system. As a result, Seoul Semiconductor has been able to reduce its annual maintenance fee by 50%, enjoy better support and can continue operating its stable, robust ERP ECC 6.0 system for a minimum of 15 additional years from the date the company switched to Rimini Street to retain full support without any forced upgrades or product migrations. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190723005031/en/ Seoul Semiconductor, a global LED development and manufacturing company headquartered in South Korea, has switched from SAP to R

Experiments Demonstrate Seoul Semiconductor SunLike Series Natural Spectrum LEDs Enhance Crop Yields, Antioxidant Content23.7.2019 13:00:00 CESTPress release

Seoul Semiconductor Co., Ltd. (KOSDAQ 046890), a leading global innovator of LED technology, announced the results of a series of experiments that demonstrated a higher growth rate and higher flavonol (antioxidant) content in crops grown under SunLike Series natural spectrum LEDs than those grown under standard white LEDs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190723005037/en/ SunLike Series LEDs Experiment Results on Crop Yields and Antioxidant Content (Graphic: Business Wire) The experiments were conducted on lettuce using SunLike Series LED lighting and standard white LED lighting of the same color temperature and light intensity. After two weeks of crop growth, the fresh weight and flavonol content of the lettuce were measured and compared. The fresh weight of lettuce grown under SunLike Series LEDs came in at 43.0g, 13.5% higher than the yield produced by standard white LEDs. In addition, the flavonol content h